-
Sept. 8, 2025， InnoCare Pharma announced that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL). At present, there are still many clinical trials of new an...Read more »
-
On August 28, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that BL-B01D1 for injection is proposed to be included in the priority review process. It is intended for patients with recurrent or metastatic nasopharyngeal carcinoma who have pre...Read more »
-
August 21，bispecific T cell engager, epcoritamab, has been granted priority review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The approval is targeted at adult patients with relapsed or refractory follicular lymphoma (FL), a high need subset o...Read more »
-
August 29,Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been approved as monotherapy by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have ...Read more »
-
On August 22, 2025, Datopotamab deruxtecan (Dato-DXd; Datroway) has received approval in China for the treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization [ISH] negative) breast...Read more »
-
In August 2025, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) officially granted Breakthrough Therapy Designation to Ina-cel, a novel CD19-directed CAR-T cell therapy independently developed by Juventas, for the treatment of pediatric patients with re...Read more »
-
20 August 2025, Abbisko Therapeutics announced that the Center forDrug Evaluation (CDE) of the China National Medical Products Administration (NlPA) has cleared the lND application for Abbisko’sinvestigational oral PD-1 inhibitor, ABSK043, combined with Shanghai Alist Pharmaceuticals KRAS ...Read more »
-
Recently，Antengene’s Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate), an elderly patient with advanced gastric cancer who has progressed on multiple lines of chemotherapy, immunotherapy and targeted therapy despite extensive metastases achieved a complete response (CR) foll...Read more »
-
On August 13, 2025, Pacific Time, the official website of the 2025 World Conference on Lung Cancer (WCLC) released the selected research abstracts for this year’s conference, Among the highlights is the updated abstract for the first-in-human Phase 1 clinical trial of HLX43, Henlius’ PD-L1 ADC. A...Read more »
-
On August 7, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that PA3-17 injection has been proposed for inclusion in the breakthrough therapy designation, intended for the treatment of adult patients with relapsed/refractory T-cell acute lymp...Read more »
-
On August 11, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) indicated that InxMed’s application for IN10018 tabletshas been proposed for breakthrough therapy designation, intended for combination with D-1553 to treat locally advanced or metastatic KRA...Read more »
-
Mr. X is a patient in his 40s diagnosed with acral melanoma. After undergoing radical surgery following his diagnosis in 2015, his condition remained stable for nine years. Unfortunately, about a year ago, his disease recurred with metastases to both lungs. Despite receiving inguinal and pelvic l...Read more »
Cooperative medical institution of
Beijing Cancer Hospital